Columbia Laboratories, Inc. Comments On FDA Decision On Adeza Biomedical's Gestiva

Published: Oct 23, 2006

LIVINGSTON, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (“FDA”) has issued an approvable letter to Adeza Biomedical for their synthetic progestogen, 17-alpha-hydroxyprogesterone caproate (trademarked “Gestiva”), Adeza’s candidate for prevention of recurrent preterm birth. Final FDA action is subject to the completion of an additional animal study and certain other conditions.

Back to news